Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described.
INTRODUCTION
Mood disorders such as depression and anxiety disorder are highly prevalent in the general population 1 and are associated with substantial morbidity and resource utilization. 2 Specifically, depression has an estimated lifetime prevalence of 16% and a 12-month prevalence of 6.6% in the United States. 3 Therefore, it is not surprising that antidepressants are one of the most commonly used medications in adults. Although antidepressants have been classified into several classes based on the mechanism of action, they are typically categorized as 'first generation' (monoamine oxidase inhibitors and tricyclic antidepressants) or 'second generation' [selective serotonin reuptake inhibitors, inhibitors of the reuptake of both serotonin and norepinephrine (SNRIs), and atypicals that have unique modes of action]. Duloxetine (Cymbalta; Eli Lilly and Company, Indianapolis, IN, USA) is one of the newer SNRIs approved in 2004 with indications for use in the treatment of major depressive disorder, diabetic neuropathy, fibromyalgia and generalized anxiety disorder. 4 Duloxetine is currently the second most commonly prescribed antidepressant with 14.4 million prescriptions written in 2008 alone. Drug-induced liver injury (DILI) from antidepressants has been reported with several agents, but data regarding duloxetine-induced liver injury are scant. In a pooled analysis of 17 615 subjects, the incidence of serum alanine aminotransferase (ALT) levels >3 times the upper limit of normal (ULN), >5 ULN and >10 ULN were 1%, 0.5% and 0.2% respectively. 5 Almost all subjects maintained normal values of alkaline phosphatase and total bilirubin with no case of jaundice and hepatocellular injury ('Hy's law') reported. 5 However, postmarketing surveillance identified 406 cases with potential hepatotoxicity from duloxetine between 8 ⁄ 2004 and 8 ⁄ 2006. 6 Of these, 58
cases were considered clinically significant. A careful review of these cases led to the following observations: (i) there was no dose-dependent increase in the incidence of hepatic injury, (ii) a large number of cases occurred between 2 and 8 weeks of therapy and 74% with onset within 16 weeks, (iii) 31% had either pre-existing liver disease or clinical risk factors for liver disease, and (iv) there were two fatal cases possibly related to duloxetine. 6, 7 These cases prompted the manufacturer, to issue a 'Dear Health Care Professional' letter and the product label was revised to include a warning that duloxetine 'should ordinarily not be prescribed to a patient with substantial alcohol use or evidence of chronic liver disease'. In this article, we report seven well-characterized consecutive cases of suspected DILI due to duloxetine enrolled in the Drug-Induced Liver Injury Network (DI-LIN) Prospective Study. Our aim is to describe their presenting clinical and laboratory features, potential risk factors and short-term outcomes.
METHODS
Seven subjects enrolled into the DILIN Prospective Study with suspected liver injury attributed to duloxetine were identified between 1 ⁄ 2006 and 9 ⁄ 2009. The DILIN Prospective Study was approved by the IRB at all participating sites. All eligible subjects provided written informed consent and were required to meet predefined eligibility criteria including being seen within 6 months of DILI onset. 8 At enrolment, a thorough evaluation was performed to assess for any competing or co-existing cause of liver injury. All clinical and laboratory data were reconciled with the source documents prior to the causality assessment as previously described. 8 Briefly, all cases were scored by expert consensus opinion on a scale of 1 (Definite) to 5 (Unlikely). For the current analysis, a single reviewer (JHH) independently calculated Roussel Uclaf Causality Assessment Method (RUCAM) and DILIN severity scores that ranged from 1 (asymptomatic) to 5 (life-threatening). imaging showed no evidence for a competing diagnosis (Table 1) . Serum acetaminophen levels at admission were undetectable, and acetaminophen-cysteine protein adducts were not detected from a sample obtained within 12 h after presentation. 9 A transjugular liver biopsy showed extensive, predominantly zone-3 liver necrosis and moderate-to-marked steatosis associated with polymorphonuclear cells with a relatively small number of mononuclear cells ( Figure 1 ). Mallory bodies were not seen. Duloxetine was discontinued and symptoms and laboratory abnormalities improved rapidly over the next 2 weeks (Figure 2 ). However, serum creatinine was 7.3 mg ⁄ dL on admission and rose to 12.3 mg ⁄ dL, eventually requiring temporary haemodialysis. He was discharged after more than a week in hospital and when seen in follow-up, 6 weeks after onset, he was asymptomatic, had resumed therapy with levothyroxine, fluoxetine and aripiprazole and all liver and kidney tests were normal.
Comment. This patient presented with severe hepatic necrosis and renal failure resembling toxic liver injury such as one that occurs with acetaminophen overdose. However, he denied use of analgesics and acetaminophen levels and adducts were not detected. The history of excessive alcohol use may have contributed to the severity of illness and affected the liver histology (accounting for steatosis and polymorphonuclear cell infiltrates), but the clinical course and liver biopsy were not compatible with acute alcoholic hepatitis alone. The DILIN causality score was 'definite' and the RUCAM score was 9 ('highly probable'). The DILIN severity score was 'severe' (4) ( Table 2) .
Patient 2
A 29-year-old Caucasian woman with chronic leg and back pain on long-term oxycodone and ibuprofen was started on duloxetine [60 mg ⁄ day] as adjuvant therapy for pain. One month later, she stopped duloxetine because of symptoms of fatigue, which she attributed to the medication. Two weeks later, she continued to have fatigue and had developed nausea, abdominal pain and dark urine. At an emergency room, she was treated with fluids and intravenous ciprofloxacin and was sent home on oral ciprofloxacin; 2 days later, she was hospitalized. She had been taking oxycodone, ibuprofen and birth control pills for several years. She did not drink alcohol and denied a history of liver disease or recent use of acetaminophen-containing products, OTC or herbal products. Blood tests showed total bilirubin of 1.8 mg ⁄ dL, Alk P 109 U ⁄ L, AST 2586 U ⁄ L, and ALT 3557 with INR of 2.0 and serum creatinine of 2.3 mg ⁄ dL. Serum acetaminophen levels were negative. The serum antinuclear antibody (ANA) titre was 1:640, but smooth muscle antibody, immunoglobulin levels were normal, tests for hepatitis A, B and C were negative, and imaging showed no evidence for biliary obstruction (Table 1) . With supportive care, she experienced rapid clinical and laboratory improvement within a month of initial testing except for the ANA, which was still positive (Figure 2 ). She restarted oxycodone and ibuprofen therapy.
Comment. This patient presented with severe acute hepatic necrosis with renal injury approximately 3 weeks after stopping a 1-month course of duloxetine. The recent exposure to ciprofloxacin provided another possible cause of liver injury, but her symptoms predated the administration of this agent. The DILIN causality score was 2 'very likely'. The RUCAM score was 5 (probable) and the DILIN severity score was 4 ( Table 2) . ). Acetaminophen levels were 7.2 lg ⁄ mL (low normal range). Tests for hepatitis A, B and C were negative as were smooth muscle and antinuclear antibodies. A small bowel series showed no evidence of obstruction. Duloxetine was discontinued on admission and liver test abnormalities began to improve rapidly ( Figure 2 ). She was discharged within 4 days due to improvement in liver tests, but was readmitted to another hospital 10 days later because of abdominal distension. Abdominal ultrasound demonstrated an enlarged liver with increased echogenicity and ascites, but no evidence of biliary obstruction and a normal spleen size. Serum bilirubin had fallen to 2.2 mg ⁄ dL and INR to 1.2 and the platelet count had risen to 149 000 ⁄ mm 3 . A liver biopsy showed steatohepatitis and bridging hepatic fibrosis, but not frank cirrhosis. An MRCP showed no evidence of biliary obstruction. She was treated with diuretics and her ascites ultimately improved. When seen in follow-up 2 years later, she no longer required diuretics and liver tests were normal.
Comment. This patient appeared to have an episode of acute hepatic necrosis superimposed upon presumed non-alcoholic steatohepatitis (NASH), which led to hepatic decompensation. The DILIN causality score was 2 'very likely', RUCAM score was 8 and DILIN severity score was 4 (jaundice and hepatic decompensation) ( Table 2) .
Patient 4
A 56-year-old Caucasian woman with depression and sciatica was started on duloxetine [30 mg ⁄ day] for pain control. Nine days later, the dose was increased to 60 mg ⁄ day. Approximately 9 weeks later, she presented with chest pain, non-specific abdominal discomfort and nausea. She had taken multiple medications for low back pain in the past, but for the previous several weeks, was only taking oxycodone, prednisone and low doses of acetaminophen. She denied use of alcohol, OTC, or HDS. Her physical examination was largely unremarkable except for jaundice. A comprehensive inpatient cardiac evaluation identified no evidence of myocardial ischaemia or dysfunction. Initial blood tests showed total bilirubin of 7.6 mg ⁄ dL, Alk P 384 U ⁄ L, AST 114 U ⁄ L and ALT 179 U ⁄ L. Tests for viral hepatitis and autoantibodies were negative, and abdominal imaging identified no evidence for biliary obstruction ( Table 1 ). The prothrombin time was normal (INR 0.9) and serum albumin 3.4 g ⁄ dL. A liver biopsy showed marked portal infiltrates composed of activated lymphocytes, which breached the limiting plates. There was also lymphocytic lobular infiltrates in a sinusoidal pattern, with a 'pseudomononucleosis' pattern, but stains for EBV antigens were negative. Kupffer cells appeared activated and rare foci of necrosis were seen as well as mild macro-and medium droplet fat. Endothelitis was present in central and portal venules. (Figure 3a,b) . Trichrome stain failed to reveal significant fibrosis. Duloxetine was stopped upon admission and symptoms and laboratory tests began to improve after 4 or 5 days, normalizing over the next 5 weeks (Figure 2 ).
Comment. This patient presented with a cholestatic hepatitis slightly more than 2 months after starting duloxetine. No other cause of acute liver injury was identified and the subsequent course was typical for a drug-induced cholestatic injury. DILIN causality score was 1 as 'definite', RUCAM score was 8 and severity grade 3 (jaundice and hospitalization without hepatic failure) ( Table 2) .
Patient 5
A 49-year-old Caucasian woman developed nausea, fatigue, dark urine and itching followed by jaundice and weight loss, 5 weeks after starting duloxetine (60 mg daily) for chronic pain and depression. She had no history of liver disease and denied use of alcohol, acetaminophen, OTC, or HDS. Physical examination showed jaundice, without fever, rash or signs of chronic liver disease. Laboratory testing showed a total bilirubin of 8.3 mg ⁄ dL, Alk P 317 U ⁄ L, AST 103 U ⁄ L and ALT 245 U ⁄ L. Serum acetaminophen levels were undetectable.
Tests for viral hepatitis were negative as was ANA, but low levels of antismooth muscle antibody were detected (32 units; normal <30 units). Serum immunoglobulin levels were normal. Duloxetine was stopped on admission, but she remained jaundiced, and serum bilirubin rose to 16.7 mg ⁄ dL with a cholestatic pattern of serum enzyme elevations (Figure 2 ). Repeat imaging studies showed no evidence of biliary obstruction and a liver biopsy showed intrahepatic cholestasis without bile duct injury or loss (Figure 4a,b) . There was no fibrosis and scant portal inflammation or evidence of chronic hepatitis. Jaundice persisted for more than 2 months, but ultimately resolved. During long-term follow-up, however, she continued to have mild elevations in serum Alk P (153 U ⁄ L, 2 years after onset).
Comment. This patient developed a prolonged and symptomatic cholestatic hepatitis, which progressively worsened for several weeks even after stopping her 1-month course of duloxetine. DILIN causality score was 2 'very likely' RUCAM score was 7 ('probable') and severity score was 3 (jaundice and hospitalization) ( Table 2) .
Patient 6
A 58-year-old African-American woman with chronic hepatitis C, diabetes, obesity, gout, chronic anxiety and chronic low back pain had duloxetine [30 mg daily] added to a chronic regimen of amitriptyline, clonazepam, oxycodone, propranolol, allopurinol, colchicine and acetaminophen. Two weeks later, she was brought to the emergency room after being found unresponsive at home. She was stuporous, but vital signs were stable. She was admitted to the intensive care unit and started on antibiotics for suspected meningitis and levetiracetam for persistent obtundation. A toxicology screen showed the presence of benzodiazepines and opiates, but no alcohol. Initial laboratory tests showed minimal liver test abnormalities with total bilirubin 0.6 mg ⁄ dL, Alk P 71 U ⁄ L, AST 81 U ⁄ L and ALT 42 U ⁄ L. Duloxetine was given intermittently, but was stopped when serum enzymes rose (ALT 125 U ⁄ L, AST 289 U ⁄ L, Alk P 78 U ⁄ L). Serum aminotransferase levels peaked several days later and then began to fall (Figure 2) . Duloxetine was restarted, but held again when ALT levels rose from 310 to 654 U ⁄ L and AST from 390 to 1269 U ⁄ L, thereafter falling to normal. Tests for hepatitis A and hepatitis B were negative. She was positive for both antibody to HCV and HCV RNA, which she was known to have had for several years. Imaging of the liver by ultrasound and CT scan showed a normal appearing liver and spleen and no evidence of biliary obstruction. After 3 weeks in the hospital, her sensorium had cleared and serum enzymes had fallen to near normal levels (ALT 61 U ⁄ L, AST 39 U ⁄ L) ( Figure 2 ) and she was discharged.
Comment. This patient had an unexplained episode of confusion and obtundation that occurred 2 weeks after starting duloxetine. During her hospitalization, restarting duloxetine was followed by prompt rises in serum ALT and AST levels, without jaundice. While the timing of serum enzyme elevations were supportive of the role of duloxetine in their aetiology, her underlying chronic hepatitis C and the multiple medications and procedures that she underwent during the hospitalization made it difficult to assign causality to duloxetine alone. DILIN causality score was 4 'possible', RUCAM score was 8 and the severity score 1 (serum enzyme elevations without jaundice) ( Table 2) .
Patient 7
A 52-year-old Caucasian woman with rheumatoid arthritis and coronary artery disease developed nausea, vomiting and abdominal pain 8 weeks after starting duloxetine [60 mg daily]. She was also taking methotrexate (started 3 years previously) and monthly infliximab infusions (for the previous 4 months). She had no history of liver disease, had normal liver tests on methotrexate and did not drink alcohol or take OTC or HDS. Physical examination was unremarkable; she was anicteric and afebrile. Laboratory testing showed total bilirubin of 0.8 mg ⁄ dL, Alk P 203 U ⁄ L, AST 719 U ⁄ L and ALT 996 U ⁄ L. Tests for hepatitis A, B, and C were negative and auto-antibodies were not present. An ultrasound showed no evidence of biliary obstruction. A liver biopsy demonstrated a mild hepatitis with lobular and portal inflammation and mild fibrosis. The dose of duloxetine was decreased and she was started on prednisone [40 mg daily]. Because of a lack of improvement in liver tests (Figure 2 ), duloxetine was discontinued 22 days after initial presentation, whereupon liver tests rapidly improved.
Comment. This patient presented with an acute hepatitis like syndrome without jaundice, which was initially not attributed to duloxetine. After a lack of improvement and development of mild jaundice, however, duloxetine was stopped, and liver tests subsequently improved and were normal during follow-up (total bilirubin 0.6 mg ⁄ dL, Alk P 48 U ⁄ L, AST 22 U ⁄ L and ALT 22 U ⁄ L approximately 100 days after the initial event was recognized). The DILIN causality score was 2 or 'very likely', RU-CAM score was 6 and severity score was 2 (jaundiced but not hospitalized) ( Table 2) .
RESULTS
A total of seven subjects were identified in the DILIN database of approximately 600 sequential cases (1% of total) with suspected hepatotoxicity from exposure to duloxetine (Table 1) . In six cases, duloxetine was the only implicated agent and causality rated either definite (n = 2) or very likely (n = 4). The median age of patients was 49 years and all except one (86%) were women ( Table 1 ). The median time to onset of symptoms or laboratory abnormalities was 50 days. Five patients had a hepatocellular pattern of serum enzyme elevations and two a cholestatic pattern. There were wide variations in the peak values of liver tests (Table 3) .
Skin rash, fever and eosinophilia, and features of immunoallergic or autoimmune hepatitis were not common. All patients showed improvement in their liver test abnormalities during the follow-up period. Three patients had underlying chronic liver disease from hepatitis C, alcoholic liver disease and NASH. In one patient with underlying chronic liver disease, new onset ascites was observed. Acute renal insufficiency occurred in two patients and bone marrow suppression (thrombocytopenia and mild leucopaenia) in one. Four of the seven cases were considered severe, demonstrating evidence of hepatic failure or accompanying bone marrow or renal failure, but all patients recovered without liver transplantation. No deaths were reported during the study follow-up.
DISCUSSION
Spontaneous reports of hepatic injury from duloxetine use to the manufacturer and FDA have raised concerns about the safety of this widely used drug. However, inherent limitations associated with such a reporting system makes causality assessment difficult and inconclusive due to incomplete information. An identifiable clinical signature and pattern of liver injury often cannot be recognized from such scant data. To date, there is only one published case report of duloxetine hepatotoxicity. 7 In this report, the investigators described various tests including serology, imaging and liver biopsy to make an argument for duloxetine hepatotoxicity. Unfortunately, this patient also received concomitant mirtazapine making the case less compelling. The current series of seven patients with liver injury after exposure to duloxetine provides a more detailed description of presentations 
Time to improve by ‡50% from peak (days) ALT T.Bili Alk P and outcomes of liver injury associated with this agent. These seven cases were enrolled between 2006 (2 years after FDA approval) and 2008 at three sites participating in the DILIN prospective study. The prospective nature of the study design and use of standardized case report forms for data capture ensured a uniformly high data capture rate and exclusion of competing causes of liver injury. The use of 'expert consensus' opinion for causality assessment not only ensured a thorough evaluation to exclude competing aetiologies conclusively but also addressed the issue of widespread variability in RUCAM scores assigned by different reviewers. 10 In the six cases attributed to duloxetine alone in our series, all of them were scored as definite or highly likely while the one case with multiple suspect drugs had a score of 'possible' duloxetine hepatotoxicity. Several observations from this case series merit attention. Hepatotoxicity from duloxetine appears to be more common at a daily dose of 60 mg compared with 30 mg (5 vs. 2 respectively). It is noteworthy that six of the affected patients were women, raising the possibility that female gender might be a risk factor for developing severe duloxetine hepatotoxicity. The onset of symptoms of liver injury averaged 6-7 weeks after staring the drug. Features of hypersensitivity (rash, fever and eosinophilia) and autoimmunity were not prominent. Three patterns of hepatic injury occurred; three patients had severe acute hepatic necrosis with a precipitous rise in serum aminotransferase levels, damage to other organs (bone marrow or kidney) and rapid recovery; two patients had a cholestatic hepatitis; and two had serum ALT and AST elevations with no or minimal jaundice. Of particular significance is, two patients with acute hepatic necrosis developed concurrent evidence of acute renal injury and one required haemodialysis. Therefore, duloxetine hepatotoxicity may be severe at presentation.
Based on postmarketing adverse event reports, alcohol abuse and pre-existing chronic liver disease have been cited as potential risk factors for duloxetine hepatotoxicity. Underlying liver disease has also been implicated in patients with isoniazid and antiretroviral hepatotoxicity. [11] [12] [13] [14] In this case series, one patient admitted to significant alcohol consumption and two others appeared to have underlying chronic liver disease (one with NASH and with chronic hepatitis C). The patient with NASH developed signs of acute liver decompensation with new onset ascites and jaundice. All patients showed improvement in their liver test abnormalities during the followup period and none required liver transplantation. No death was reported during the study follow-up.
Patients with underlying liver disease may be at increased risk of developing DILI due to increased intrahepatic immune activity, altered drug toxification ⁄ detoxification pathways, etc. As patients with mood disorders frequently have underlying liver disease, a careful consideration of the risk vs. benefit of duloxetine in patients with liver disease is recommended. As a minimum, assessing baseline liver biochemistries would be advisable as well as repeat laboratory monitoring during the first 12-16 weeks of duloxetine therapy. In addition, a careful and slow titration of the duloxetine dose would be advisable particularly in patients with pre-existing liver disease. The lack of hypersensitivity features noted in our series does not entirely exclude an immunological mechanism in duloxetine hepatotoxicity, as was recently shown with flucloxacillin hepatoxicity. 15 Therefore, collection of DNA samples from well-characterized cases like these enrolled in the DILIN study and other registries around the world may allow for future mechanistic investigation of the potential role of host genetic factors in these rare adverse events. In summary, duloxetine-induced liver injury appears to be idiosyncratic in nature and its onset is within 2 months after its initiation. Several patterns of hepatic injury (signatures) occur, including hepatocellular and cholestatic features. The available liver histology is highly variable. Acute kidney failure or other organ involvement may occur. The hepatic injury can be severe, although full recovery is the usual outcome. This report raises the possibility that duloxetine administered at 60 mg ⁄ day is more hepatotoxic than 30 mg daily dose. The relationship between duloxetine hepatotoxicity and underlying liver disease and female gender requires further investigation. Physicians using this drug should be aware of the spectrum of liver injury and consider duloxetine as another agent capable of causing life-threatening liver injury. In patients with underlying liver disease, slow and deliberate dosage titration with careful monitoring for adverse hepatic effects in the first few months of duloxetine therapy is suggested.
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